SCHEMBL30191093

SCHEMBL30191093

Cc1cc(N2CCN(C)CC2)ccc1N

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.69
MAPT P10636 4/20 0.69
KDM4E B2RXH2 3/20 0.69
PTK2B Q14289 2/20 0.69
MAPK1 P28482 2/20 0.69
HTT P42858 2/20 0.69
RECQL P46063 1/20 0.69
RAD52 P43351 1/20 0.68
ALDH1A1 P00352 4/20 0.58
ADRA2C P18825 3/20 0.58
KMT2A Q03164 3/20 0.58
GFER P55789 1/20 0.58
ESR2 Q92731 1/20 0.58
SIRT6 Q8N6T7 2/20 0.54
HTR3A P46098 1/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
MEN1 O00255 2/20 0.49
GLA P06280 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6150891 1.00 GAA (0.69) GAAMAPTKDM4EPTK2BMAPK1
SCHEMBL6151809 1.00 GAA (0.69) GAAMAPTKDM4EPTK2BMAPK1
SCHEMBL519972 1.00 GAA (0.69) GAAMAPTKDM4EPTK2BMAPK1
SCHEMBL5203985 0.93 GAA (0.61) GAAMAPTKDM4EPTK2BMAPK1
SCHEMBL6151434 0.92 GAA (0.77) GAAMAPTKDM4EPTK2BMAPK1
SCHEMBL15358759 0.92 GAA (0.77) GAAMAPTKDM4EPTK2BMAPK1
SCHEMBL6266805 0.87 GAA (0.70) GAAMAPTKDM4EPTK2BMAPK1
SCHEMBL1527203 0.85 GAA (0.64) GAAMAPTKDM4EPTK2BMAPK1
SCHEMBL30900439 0.85 GAA (0.64) GAAMAPTKDM4EPTK2BMAPK1
SCHEMBL23126674 0.85 GAA (0.55) GAAMAPTKDM4EPTK2BMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4402127-A1 AMINOPYRIDINES AS ACTIVATORS OF PI3 KINASE UCL Business Ltd (GB) 2024-07-24 EP disclosed
CN-116669725-A Novel aminopyridine and use thereof in the treatment of cancer 奥克兰联合服务有限公司 2023-08-29 CN disclosed
CN-116529251-A Substituted fused bicyclic compounds as kinase inhibitors and their use 上海瑛派药业有限公司 2023-08-01 CN disclosed
WO-2023138412-A1 FUSED PYRIMIDIN-2-AMINE COMPOUNDS AS CDK20 INHIBITORS INSILICO MEDICINE IP LIMITED (CN) 2023-07-27 WO disclosed
WO-2023041905-A1 AMINOPYRIDINES AS ACTIVATORS OF PI3 KINASE UCL BUSINESS LTD (GB) 2023-03-23 WO disclosed
US-20230009626-A1 INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS ICHNOS SCIENCES S.A. (CH) 2023-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230009626-A1 INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS MAP4K1, MAP4K2, MAP4K4 GAA 3596/4885MAPT 142/4885KDM4E 1118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.